原發(fā)性前列腺印戒細(xì)胞癌6例報(bào)告及文獻(xiàn)復(fù)習(xí)
ABSTRACT:ObjectiveTo explore the diagnosis, treatment and prognosis of primary prostatic signet ring cell carcinoma (SRCC), so as to provide reference for the clinical diagnosis and treatment.MethodsA retrospective analysis was conducted on the clinical data of 6 patients with primary prostatic SRCC treated in Nanjing Drum Tower Hospital during Nov.2020 and Sep.2024.The clinical manifestations, imaging features, treatment methods, histological characteristics and prognosis were summarized.ResultsThe average age of the patients was (72.00±4.28) years.Varying degrees of dysuria occurred in 4 patients.All patients underwent multi-parametric magnetic resonance imaging (mpMRI) examination before surgery, and the results indicated typical prostate cancer.Preoperative biopsies showed high-grade (Gleason 810)prostate acinar adenocarcinoma.Postoperative pathological diagnoses were mixed types of prostate acinar adenocarcinoma and SRCC, and no metastasis was found in the pelvic lymph nodes.All patients were followed up for 1 to 46 months after surgery and are currently alive.Robot-assisted laparoscopic radical prostatectomy only was performed in 3 cases; apalutamide and leuprolide/triptorelin was administered after surgery in 2 cases; bicalutamide + goserelin was administered after surgery in 1 case, who developed bladder metastasis of prostate cancer 24 months later, and the serum prostate-specific antigen (PSA) concentration decreased to a safe level (<0.2 ng/mL) after the use of darolutamide with radiotherapy.No recurrence or metastasis was found in the remaining patients.ConclusionPrimary prostatic SRCC is a rare and highly aggressive malignant tumor of the prostate.The diagnosis depends on pathological examinations due to lack of specific imaging features and clinical manifestations.The prognosis is poor, and there is currently no standardized treatment.The combined use of surgery, hormonotherapy and radiotherapy can help improve the survival rate of patients.
摘要:目的探討原發(fā)性前列腺印戒細(xì)胞癌(SRCC)的診斷、治療及預(yù)后,為該病的臨床診治提供參考。(剩余10980字)
-
-
- 現(xiàn)代泌尿外科雜志
- 2025年04期
- 中國(guó)人口老齡化背景下老年尿失禁...
- 長(zhǎng)段輸尿管狹窄外科治療思考:不...
- 脊髓損傷患者膀胱管理的影響因素...
- 原發(fā)性前列腺印戒細(xì)胞癌6例報(bào)告...
- 經(jīng)腹腔入路與腹膜后入路機(jī)器人輔...
- 可視擴(kuò)張鞘聯(lián)合針狀腎鏡經(jīng)皮腎鏡...
- 輸尿管開(kāi)口完整切除技術(shù)在膀胱癌...
- 智能控溫控壓輸尿管軟鏡聯(lián)合負(fù)壓...
- 一體位機(jī)器人輔助腹腔鏡與后腹腔...
- 非肌層浸潤(rùn)性膀胱癌患者首次經(jīng)尿...
- 兒童陰莖金屬螺母嵌頓1例報(bào)告并...
- 精索內(nèi)靜脈-大隱靜脈分流術(shù)治療...
- 一種創(chuàng)新的輸尿管回腸吻合方法...
- 機(jī)械敏感通道Piezo 1和P...
- 機(jī)器人輔助腹腔鏡下根治性前列腺...
- 基于解剖特征預(yù)測(cè)腎腫瘤手術(shù)難度...
- 雙鏡聯(lián)合下改良膀胱部分切除術(shù)治...
- 導(dǎo)尿后出現(xiàn)活動(dòng)性尿道出血并假性...